Cadrenal Therapeutics, Inc. (CVKD)
1.03
+0.03
(+3.00%)
USD |
NASDAQ |
Nov 06, 10:11
Cadrenal Therapeutics Debt to Equity Ratio : 0.00 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.0006 |
| June 30, 2024 | 0.0022 |
| Date | Value |
|---|---|
| March 31, 2024 | 0.0025 |
| December 31, 2023 | 0.0028 |
| September 30, 2023 | 0.0031 |
| June 30, 2023 | 0.0104 |
| March 31, 2023 | 0.0094 |
| December 31, 2022 | -0.1154 |
| September 30, 2022 | -0.448 |
| June 30, 2022 | -0.6336 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ANI Pharmaceuticals, Inc. | 1.022 |
| Corcept Therapeutics, Inc. | 0.0108 |
| Veru, Inc. | 0.0945 |
| Johnson & Johnson | 0.5477 |
| Eli Lilly & Co. | 1.229 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 5.589M |
| Total Liabilities (Quarterly) | 1.497M |
| Shareholders Equity (Quarterly) | 4.092M |
| Current Ratio | 3.666 |